BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

Qiagen to remain independent Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to be acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen shareholders, well below the...
BioCentury | Jul 18, 2019
Distillery Therapeutics

Small molecule NPR1 inhibitors for itch

DISEASE CATEGORY: Dermatology INDICATION: Itch NIH researchers identified 15 small molecule human NPR1 inhibitors through cell-based screening that could treat itch. The compounds inhibited NRP1, a receptor for a neuropeptide that promotes itch, with IC...
BioCentury | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
BioCentury | Mar 21, 2018
Company News

Weather delay for achondroplasia meeting

FDA postponed until further notice the March 22 joint meeting of the Pediatric Advisory Committee (PAC) and Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) due to inclement weather. The committees are slated to discuss drug...
BioCentury | Apr 6, 2017
Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...
BioCentury | Dec 14, 2016
Clinical News

Vosoritide: Ph III started

BioMarin began a double-blind, placebo-controlled, international Phase III trial to evaluate daily vosoritide for 52 weeks in about 110 patients ages 5-14. Patients who complete the trial may be eligible to enroll in an open-label...
BioCentury | Apr 13, 2015
Clinical News

Cenderitide: Completed Phase II enrollment

Capricor completed enrollment of 14 patients in an open-label, dose-escalation, U.S. Phase II trial evaluating 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusion via Insulet’s OmniPod drug delivery system...
BioCentury | Mar 9, 2015
Clinical News

Cenderitide: Phase II started

Capricor began an open-label, dose-escalation, U.S. Phase II trial to evaluate 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet Drug Delivery System for up to 8 days...
BioCentury | Nov 24, 2014
Company News

Medtronic, Capricor Therapeutics deal

Capricor purchased Medtronic’s patent related to the formulation and pump delivery of natriuretic peptides to treat post-acute heart failure. Medtronic will receive a $100,000 upfront payment and is eligible for $7 million in milestones. Medtronic...
BioCentury | Jul 15, 2013
Company News

Capricor, Nile Therapeutics deal

Capricor will reverse-merge with Nile in a stock deal. Nile will issue Capricor stockholders shares of Nile stock so that Capricor will own about 90% of the combined company, which will be called Capricor Therapeutics...
Items per page:
1 - 10 of 62